Connect with us

L.A.’s Homeless: Advocates Blast County, Mayor Garcetti for Delaying Release 2019 Homeless Numbers

Published

on

Reading Time: 2 minutes

Formal release of 2019 numbers now pushed to Tuesday, June 4th
instead of the customary May 31
st release. Move
suggests sharper increase in homeless count than what advocates and
officials might have anticipated despite over $619 million in gov’t
spending on homeless in the region over the last year.

Official homeless count in Los Angeles in 2018 was 53,195.

LOS ANGELES–(BUSINESS WIRE)–Housing justice and homeless advocates with Housing
Is A Human Right
, Healthy
Housing Foundation by AHF
, Coalition
to Preserve LA
, AIDS Healthcare Foundation (AHF)
today blasted Los Angeles politicians and bureaucrats for their ongoing
lackluster response to the human catastrophe of homelessness in Los
Angeles. The rebuke, specifically targeting Mayor Eric Garcetti and the
County Board of Supervisors, was prompted by today’s word of a delay in
the formal release of the 2019 homeless count, traditionally released by
May 31st each year, but now pushed to Tuesday, June 4th.

“The last minute, unexpected delay of the release of L.A.’s 2019
homeless count to next Tuesday suggests that there’s been a sharper
increase in the homeless numbers than what advocates and officials might
have anticipated, despite over $619 million in government spending on
the homeless in the region over the last year,” said Michael Weinstein,
president, AHF. “Delay, inaction and spin: Why? This allows Mayor
Garcetti, City Council and the Board of Supervisors time to spin away
their outdated, expensive—and clearly ineffectual—response to the
homeless crisis we actually have here in Los Angeles. The official
response on homelessness simply does not correlate to the crisis we face
and our elected officials just continue to move at the speed of
government. It’s a national disgrace.”

Homeless advocates’ criticisms of the response to L.A.’s homeless and
affordable housing crises include:

  • City Council’s continual approval of development projects with NO
    designated affordable or extremely low-income housing units (recent
    unanimous 14-0 vote to approve a 725-unit Chinatown project with NO
    affordable units. Councilman Gil Cedillo overrode recommendation that
    37 units be set aside as affordable for very low-income tenants).
  • The astronomic price tag—well over $500K per unit—of so called
    ‘affordable’ housing units under the Measure HHH bond.
  • The fact that NO homeless individual has been housed yet under
    HHH—three years after L.A. voters approved the $1.2B bond in Nov.
    2016).
  • City Council’s refusal to ban campaign contributions from developers
    and real estate interests (again, Councilman Cedillo: “I’m not
    quite sure — what’s the problem we’re trying to solve?”
    ).
  • City Council’s razing and destruction of Parker Center to build a
    luxury corporate L.A. government tower for city employees, despite the
    fact that housing advocates commissioned feasible plans to turn the
    former police HQ into housing units for over 700 homeless individuals.
  • The city’s ongoing and inhumane homeless rousting policies and
    confiscation and destruction of homeless individuals’ belongings.
  • The city and county’s failure to explore and adopt an ‘adaptive reuse’
    approach to housing the homeless by purchasing and repurposing
    old—already existing—un- and under-occupied single room occupancy
    (SRO) hotels throughout Los Angeles (by some estimates there are over
    10,000 such rooms in hotels in L.A.)

For more information on housing and homeless advocates’ concerns, please
visit: LAScandal.org.

Contacts

Ged Kenslea, Senior Director, Communications,
+1.323.791.5526 cell gedk@aidshealth.org
Marin
Austin
, Communications Director, +1323.333.7754 cell marin.austin@aidshealth.org

Cannabis

One Year of Medical Cannabis in the UK, Data by Grow Biotech

Published

on

Photo source: southeusummit.com

 

The 1st of November 2019 will mark the one year anniversary of the legalisation of medical cannabis in the United Kingdom. A year after Charlotte Caldwell’s tireless campaign to obtain life-saving medication for her son Billy catapulted medical cannabis onto the public agenda, the cost of prescriptions has dropped substantially while the number of scripts written has increased, but more needs to be done before it can be more widely offered by the National Health Service (NHS).

The average price of a month’s supply of medical cannabis imported through Logist has dropped from £750 to £550, reducing the average monthly prescription cost by 27%, while the average price per gram has also fallen by 25%. The reduction in cost is a combination of increased volume (meaning the costs associated with importing products is lower per prescription) and the increased availability of different products.

The type of medical specialist consultants writing prescriptions for medical cannabis has also diversified to include pain, oncology and neurology. There has also been a broadening in the delivery method for medical cannabis requested by specialist consultants to include different cannabis oils, pills and flowers, which is largely a result of the greater range of products available. Since February, Logist has imported approximately 1.5kg of flower to the UK.

The vast majority of medical cannabis has made its way to the UK thanks to Logist, a joint-venture formed between specials importer IPS Pharma, and Grow Biotech, the UK’s leading medical cannabis market access specialists.

Timeline of Events

  • 1st November 2018 – New regulations introduced, which allowed for the import and prescription of cannabis-based medicines
  • 14 February 2019 – The first bulk import of medical cannabis in the UK and first patients to receive medication from Logist
  • May 2019 – EU based bio-pharmaceutical company MGC Pharma appoints Logist
  • August 2019 – NICE publish interim report on medical cannabis
  • August 2019 – American medical cannabis giant Columbia Care announces that it will fund and provide medicine for clinical trials in the UK
  • September 2019– Leading Canadian company Aurora appoints IPS Pharma and Grow Biotech as importer and distributor for the UK market
  • September 2019 – Medical cannabis consultant informs Logist that a patient is no longer using opioids to manage their condition following treatment with medical cannabis

Looking forward to the near future, Chief Operating Officer of Grow Biotech, Hari Guliani, said, “Over the next twelve months we expect the UK’s medical community as a whole to take on the challenge of understanding how cannabis might help their patients. We are expecting leading consultants to publish papers on the impact they have seen on their patients, as well as evidence gathered through MHRA-approved trials. This will significantly improve the data available to regulators, policymakers and NICE.”

At present, it is only available on the NHS in extremely limited circumstances and is only obtainable through a prescription written by a specialist consultant in the private sector. NICE (The National Institute of Health Care Excellence) has advised that more clinical trials need to be undertaken in the UK and overall costs of medication need to be reduced before medical cannabis can be prescribed by NHS consultants. However, new medical trials are now underway and prices associated with the import of medical cannabis are falling dramatically, giving hope to the thousands of patients who are still struggling to access life-changing medication.

Another major change which cannot be overlooked is funding for the UK’s young medical cannabis industry. Ben Langley, Chief Executive Officer of Grow Biotech explained that, “We have seen a massive increase in funding for UK businesses operating within the medical cannabis space, especially from North America. In addition to the £5m Grow Biotech has raised over the last two years, there have been notably well received fundraises for Emmac Life Sciences PLC (£11m raised in March 2019) and for Oxford Cannabinoid Therapeutics ($10m in April 2019). This trend is likely to accelerate as European medical cannabis gradually establishes itself as an attractive asset class for global capital and European equity exchanges start to open their doors to cannabis companies.

Both Ben Langley and Hari Guliani are available for comment and interview.

 

SOURCE Grow Biotech

Continue Reading

Cannabis

GNCC Capital, Inc. – Pending Transaction

Published

on

 

GNCC Capital, Inc. (OTC: GNCP) (“The Company” or “GNCC”) advises that the new Board of Directors is in the process of consummating a further transaction in the Cannabis Sector and in South Africa.

Given that this is a related party transaction; they are awaiting ratification from an Independent party.

Upon consummation of this transaction; the new GNCC Directors will actively engage with shareholders. This decision was taken given that this transaction materially affects the size and scope of the Company’s South African Cannabis interests.

We reiterate that both Ms. Allen and Mr. Cox have recognized the need to; and have committed to expend the next two to three weeks in shareholder engagement. This is to ensure that all shareholders and investors become familiar with the Company’s new business operations, opportunities, Licensing and the Cannabis Industry in South Africa.

Forward-Looking Statements:-This press release may contain forward-looking statements. The words “believe,” “expect,” “should,” “intend,” “estimate,” “projects,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company’s current expectations and are subject to a number of risks, uncertainties and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company’s filings, which are on file with the OTC Markets Group.

SOURCE GNCC Capital, Inc.

Continue Reading

Cannabis

Empower Clinics Provides Corporate Updates Highlighting Triple Digit Patient Growth and Subsidiary Sun Valley Health Launches New Modalities and Patient Services

Published

on

 

EMPOWER CLINICS INC. (CSE: CBDT) (OTC: EPWCF) (Frankfurt 8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company, a multi-state operator of medical health & wellness clinics, a CBD product producer and operator of an extraction facility in Oregon, is pleased to announce it is launching seven new modalities and services for patients in the Sun Valley Health clinics commencing Monday October 14th, 2019.

The Company also has patient visits in corporate clinics increase by triple digits, with September 2019 patients seen increasing by 307% to 1,884 versus September 2018 with 614 patients seen.

“The tremendous year-over-year increase in patient visits is a testament to the operating strengths and patient management demonstrated by our clinic team members, each and every day,” said Steven McAuley, CEO of Empower. “Their passion for patient wellbeing and the use of numerous communication tools ensures world-class service is provided throughout the entire patient journey.”

As part of the Company’s continued expansion of our health & wellness clinic model, we have already set up retail CBD product sales in-clinic, and now we have launched expanded physician based services.

New Modalities and Services

  • Physician’s CBD Enhanced Massage, Acupuncture, or Cupping Sessions
  • CBD-Cannabis-Supplement Consumption & Coaching Consultation
  • Introduction to Alternative Health and Cannabinoid Therapies by a Physician
  • Comprehensive Naturopathic Patient Analysis & Consultation
  • Dietary Antigen Testing, Physician Consultation/Action Plan, & Concierge Blood Draw
  • Neurotransmitter (urine) Profile & Physician Consultation/Action Plan
  • Spectracell Micronutrient Test & Physician Consultation/Action Plan

“By offering our new suite of laboratory testing, alternative health consulting, and CBD therapies we are able to address the needs of our current patients and serve the community outside of cannabis that are seeking alternative health care,” states Dustin Klein, Director & VP Business Development. “Incorporating our new modalities, high quality vitamins, supplements, and CBD products into our network of clinics is a natural progression toward our goal of becoming the nation’s premier alternative healthcare provider.”

Additional UPDATES

  • New Modalities and Patient Services The Company continues to see patient visits in corporate clinics increase by triple digits, with September 2019 patients seen increasing by 307% to 1,884 over July 2018 614 patients seen.

  • Sun Valley Health Franchise Sun Valley Health www.sunvalleyhealth.com has been actively participating in various franchise and cannabis expos in St. LouisChicago and Houston to market the Sun Valley Health franchise program, attracting numerous qualified candidates for available territory locations. The Company has accepted many applications and has provided the Franchise Disclosure Document (FDD) to qualified applicants in anticipation of completing the first initial territory sales.

 

SOURCE Empower Clinics Inc.

Continue Reading

Trending Online

Grassnews is a news publishing website which digests / hand picks the latest news about the cannabis industry, and serves them to you daily.

Contact us: pressroom@grassnews.net

© Grassnews.net 2019 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania